Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant

Curtis R. Brandt, Pascal D. Imesch, Nancy L. Robinson, Nasreen A. Syed, Seema Untawale, Soesiawati R. Darjatmoko, Richard J. Chappell, Paul Heinzelman, Daniel Albert

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The use of viruses to treat tumors has received renewed interest with the availability of genetically defined attenuated mutants. Herpes simplex virus (HSV) type 1 in particular has been shown to be effective for tumors of neuronal origin. However, the model systems used for these studies rely on the use of explanted tumor cells in immunodeficient animals. We have used a recently developed transgenic mouse model, wherein mice spontaneously develop retinoblastomas, to determine if a mutant HSV has a therapeutic effect against an endogenously arising tumor in an immunocompetent host. The injection of 1 x 106 PFU of the neuroattenuated HSV-1/HSV-2 recombinant RE6 into the vitreous of transgenic mice resulted in a significant inhibition of tumor growth compared to injection of medium alone (P = 0.0063). Immunohistochemical analysis of viral antigen showed that viral replication was restricted to focal areas of the tumors and the retinal pigment epithelium. Viral growth was not significantly different in the eyes of transgene-positive and transgene-negative mice, suggesting that enhanced replication in tumor cells may not explain the effects. Tumor cells in the treated eyes were significantly less differentiated than those in the untreated eyes (P = 0.04), suggesting that the virus may replicate better in certain cell types in the tumors. Although the injection of RE6 resulted in a difference in tumor size, the treatment did not result in the elimination of tumors in any of the mice. Improvements in the efficacy of tumor control are needed if this therapy is to be of use.

Original languageEnglish (US)
Pages (from-to)283-291
Number of pages9
JournalVirology
Volume229
Issue number1
DOIs
StatePublished - Mar 3 1997
Externally publishedYes

Fingerprint

Retinoblastoma
Simplexvirus
Transgenic Mice
Neoplasms
Therapeutics
Human Herpesvirus 1
Transgenes
Injections
Viruses
Human Herpesvirus 2
Viral Antigens
Retinal Pigment Epithelium
Therapeutic Uses
Growth

ASJC Scopus subject areas

  • Virology

Cite this

Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. / Brandt, Curtis R.; Imesch, Pascal D.; Robinson, Nancy L.; Syed, Nasreen A.; Untawale, Seema; Darjatmoko, Soesiawati R.; Chappell, Richard J.; Heinzelman, Paul; Albert, Daniel.

In: Virology, Vol. 229, No. 1, 03.03.1997, p. 283-291.

Research output: Contribution to journalArticle

Brandt, CR, Imesch, PD, Robinson, NL, Syed, NA, Untawale, S, Darjatmoko, SR, Chappell, RJ, Heinzelman, P & Albert, D 1997, 'Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant', Virology, vol. 229, no. 1, pp. 283-291. https://doi.org/10.1006/viro.1996.8414
Brandt, Curtis R. ; Imesch, Pascal D. ; Robinson, Nancy L. ; Syed, Nasreen A. ; Untawale, Seema ; Darjatmoko, Soesiawati R. ; Chappell, Richard J. ; Heinzelman, Paul ; Albert, Daniel. / Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. In: Virology. 1997 ; Vol. 229, No. 1. pp. 283-291.
@article{a93ed0fa678f4c07abfa43962ad6256c,
title = "Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant",
abstract = "The use of viruses to treat tumors has received renewed interest with the availability of genetically defined attenuated mutants. Herpes simplex virus (HSV) type 1 in particular has been shown to be effective for tumors of neuronal origin. However, the model systems used for these studies rely on the use of explanted tumor cells in immunodeficient animals. We have used a recently developed transgenic mouse model, wherein mice spontaneously develop retinoblastomas, to determine if a mutant HSV has a therapeutic effect against an endogenously arising tumor in an immunocompetent host. The injection of 1 x 106 PFU of the neuroattenuated HSV-1/HSV-2 recombinant RE6 into the vitreous of transgenic mice resulted in a significant inhibition of tumor growth compared to injection of medium alone (P = 0.0063). Immunohistochemical analysis of viral antigen showed that viral replication was restricted to focal areas of the tumors and the retinal pigment epithelium. Viral growth was not significantly different in the eyes of transgene-positive and transgene-negative mice, suggesting that enhanced replication in tumor cells may not explain the effects. Tumor cells in the treated eyes were significantly less differentiated than those in the untreated eyes (P = 0.04), suggesting that the virus may replicate better in certain cell types in the tumors. Although the injection of RE6 resulted in a difference in tumor size, the treatment did not result in the elimination of tumors in any of the mice. Improvements in the efficacy of tumor control are needed if this therapy is to be of use.",
author = "Brandt, {Curtis R.} and Imesch, {Pascal D.} and Robinson, {Nancy L.} and Syed, {Nasreen A.} and Seema Untawale and Darjatmoko, {Soesiawati R.} and Chappell, {Richard J.} and Paul Heinzelman and Daniel Albert",
year = "1997",
month = "3",
day = "3",
doi = "10.1006/viro.1996.8414",
language = "English (US)",
volume = "229",
pages = "283--291",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant

AU - Brandt, Curtis R.

AU - Imesch, Pascal D.

AU - Robinson, Nancy L.

AU - Syed, Nasreen A.

AU - Untawale, Seema

AU - Darjatmoko, Soesiawati R.

AU - Chappell, Richard J.

AU - Heinzelman, Paul

AU - Albert, Daniel

PY - 1997/3/3

Y1 - 1997/3/3

N2 - The use of viruses to treat tumors has received renewed interest with the availability of genetically defined attenuated mutants. Herpes simplex virus (HSV) type 1 in particular has been shown to be effective for tumors of neuronal origin. However, the model systems used for these studies rely on the use of explanted tumor cells in immunodeficient animals. We have used a recently developed transgenic mouse model, wherein mice spontaneously develop retinoblastomas, to determine if a mutant HSV has a therapeutic effect against an endogenously arising tumor in an immunocompetent host. The injection of 1 x 106 PFU of the neuroattenuated HSV-1/HSV-2 recombinant RE6 into the vitreous of transgenic mice resulted in a significant inhibition of tumor growth compared to injection of medium alone (P = 0.0063). Immunohistochemical analysis of viral antigen showed that viral replication was restricted to focal areas of the tumors and the retinal pigment epithelium. Viral growth was not significantly different in the eyes of transgene-positive and transgene-negative mice, suggesting that enhanced replication in tumor cells may not explain the effects. Tumor cells in the treated eyes were significantly less differentiated than those in the untreated eyes (P = 0.04), suggesting that the virus may replicate better in certain cell types in the tumors. Although the injection of RE6 resulted in a difference in tumor size, the treatment did not result in the elimination of tumors in any of the mice. Improvements in the efficacy of tumor control are needed if this therapy is to be of use.

AB - The use of viruses to treat tumors has received renewed interest with the availability of genetically defined attenuated mutants. Herpes simplex virus (HSV) type 1 in particular has been shown to be effective for tumors of neuronal origin. However, the model systems used for these studies rely on the use of explanted tumor cells in immunodeficient animals. We have used a recently developed transgenic mouse model, wherein mice spontaneously develop retinoblastomas, to determine if a mutant HSV has a therapeutic effect against an endogenously arising tumor in an immunocompetent host. The injection of 1 x 106 PFU of the neuroattenuated HSV-1/HSV-2 recombinant RE6 into the vitreous of transgenic mice resulted in a significant inhibition of tumor growth compared to injection of medium alone (P = 0.0063). Immunohistochemical analysis of viral antigen showed that viral replication was restricted to focal areas of the tumors and the retinal pigment epithelium. Viral growth was not significantly different in the eyes of transgene-positive and transgene-negative mice, suggesting that enhanced replication in tumor cells may not explain the effects. Tumor cells in the treated eyes were significantly less differentiated than those in the untreated eyes (P = 0.04), suggesting that the virus may replicate better in certain cell types in the tumors. Although the injection of RE6 resulted in a difference in tumor size, the treatment did not result in the elimination of tumors in any of the mice. Improvements in the efficacy of tumor control are needed if this therapy is to be of use.

UR - http://www.scopus.com/inward/record.url?scp=0031550775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031550775&partnerID=8YFLogxK

U2 - 10.1006/viro.1996.8414

DO - 10.1006/viro.1996.8414

M3 - Article

C2 - 9123872

AN - SCOPUS:0031550775

VL - 229

SP - 283

EP - 291

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -